Payment overview · 2025
General Payments
$3,788.98
63 reported records · 18 companies
Healthcare provider profile · identity verified
Tory August Torma, DO
Allopathic & Osteopathic Physicians|Internal Medicine · DANVILLE, KY · NPI 1194255448
Verified facts
What the public records show
CMS Open Payments records show Tory August Torma, DO received $3,788.98 in general payments during 2025 across 63 reported records.
ABBVIE INC. accounted for 80.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Qulipta, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,032.98 | 80.0% | 28 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $153.00 | 4.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $122.89 | 3.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.93 | 2.4% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.94 | 2.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.78 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.80 | 0.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.63 | 0.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.13 | 0.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.05 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.48 | 0.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.71 | 0.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.15 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.09 | 0.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.84 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.57 | 0.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.83 | 0.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.18 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,750.00 | 2 |
| Food and Beverage | $1,038.98 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $1,552.63 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $1,532.72 | 21 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $153.00 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $122.89 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.00 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $80.94 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.97 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.78 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.63 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 185 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 103 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
103 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
185 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
115 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 451 | 68 |
| Lisinopril | Lisinopril | 446 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 418 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 110 |
| Omeprazole | Omeprazole | 332 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 331 | 95 |
| Losartan Potassium | Losartan Potassium | 324 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 71 |
| Potassium Chloride | Potassium Chloride | 213 | 66 |
| Tramadol Hcl | Tramadol Hcl | 211 | 40 |
| Furosemide | Furosemide | 201 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 61 |
| Metformin Hcl | Metformin Hcl | 185 | 56 |
| Mounjaro | Tirzepatide | 185 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 182 | 46 |
| Trazodone Hcl | Trazodone Hcl | 150 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 35 |
| Buspirone Hcl | Buspirone Hcl | 138 | 41 |
| Clonazepam | Clonazepam | 131 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 43 |
| Pregabalin | Pregabalin | 125 | 33 |
| Alendronate Sodium | Alendronate Sodium | 122 | 30 |
| Trulicity | Dulaglutide | 115 | 24 |
| Carvedilol | Carvedilol | 108 | 34 |
| Meloxicam | Meloxicam | 107 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 21 |
| Prednisone | Prednisone | 101 | 81 |
| Famotidine | Famotidine | 95 | 34 |
| Montelukast Sodium | Montelukast Sodium | 95 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 13 |
| Jardiance | Empagliflozin | 91 | 19 |
| Simvastatin | Simvastatin | 91 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 23 |
| Farxiga | Dapagliflozin Propanediol | 75 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 26 |
| Glipizide | Glipizide | 71 | 18 |
| Atenolol | Atenolol | 70 | 24 |
| Metformin Hcl Er | Metformin Hcl | 68 | 18 |
| Ondansetron Odt | Ondansetron | 65 | 32 |
| Synthroid | Levothyroxine Sodium | 65 | 21 |
| Allopurinol | Allopurinol | 64 | 21 |
| Sertraline Hcl | Sertraline Hcl | 63 | 20 |
| Ezetimibe | Ezetimibe | 61 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 14 |
| Ozempic | Semaglutide | 59 | 15 |
| Celecoxib | Celecoxib | 58 | 14 |
| Alprazolam | Alprazolam | 57 | 11 |
| Repatha Sureclick | Evolocumab | 57 | 11 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Methocarbamol | Methocarbamol | 55 | 22 |
| Glipizide Er | Glipizide | 54 | 16 |
| Nifedipine Er | Nifedipine | 50 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 12 |
| Eliquis | Apixaban | 48 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 15 |
| Ubrelvy | Ubrogepant | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Qulipta | Atogepant | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Fluconazole | Fluconazole | 26 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 20 |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,788.98 · 63 records | ABBVIE INC. | Auvelity, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, Kerendia, Korlym, MOUNJARO, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error